Role of immunotherapy in carcinoma ovary, in upfront and recurrent settings, rationale of combining immunotherapy with parp inhibitors , detailed overview using all the evidences, in detail, include all latest evidences also. Describe Using tables/ flowchart s wherever applicable. Also mention about latest guidelines for immunotherapy in ovarian cancer.
immunotherapy ovarian cancer checkpoint inhibitor
PARP inhibitor immunotherapy combination ovarian cancer
NCCN ESMO guidelines immunotherapy ovarian cancer 2024 2025 pembrolizumab nivolumab
PMID: 41763143
PMID: 42155872
PMID: 40461381
PMID: 39764856
https://pmc.ncbi.nlm.nih.gov/articles/PMC12730224
PMID: 36992842
PMID: 40650991
KEYNOTE-B96 pembrolizumab paclitaxel ovarian cancer platinum-resistant
IMagyn050 atezolizumab ovarian cancer first-line PAOLA-1 durvalumab
PMID: 41974150
PMID: 42362076
PAOLA-1 durvalumab bevacizumab olaparib ovarian cancer maintenance
KEYNOTE-B96 pembrolizumab FDA approval February 2026 ovarian cancer platinum resistant results
PARP inhibitor immune checkpoint immunosuppression cGAS STING ovarian tumor microenvironment
DUO-O ENGOT-OV46 durvalumab olaparib bevacizumab first-line ovarian cancer
Quick Orientation
Key Takeaways at a Glance
| Setting | ICI Role | Evidence Level | Guideline Status |
|---|---|---|---|
| 1st Line (upfront) | Investigational only | Multiple negative Phase III trials | NOT standard (NCCN/ESMO 2026) |
| Platinum-sensitive recurrence | Not effective | Negative trials (JAVELIN, others) | NOT recommended |
| Platinum-resistant recurrence (PD-L1 CPS ≥1) | APPROVED | KEYNOTE-B96 Phase III (Lancet 2026) | FDA/EMA approved Feb-Apr 2026 |
| PARPi + ICI combination | Modest benefit in selected biomarker groups | Phase III trials + 2026 meta-analyses | Not standard; active trial area |